Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Poupak Fallahi

Showing results (251-260 of 270) with videos related to

Pageof 27
Sort By:
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Cancers|December 9, 2020
Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational StudySalvatore Sorrenti, Giovanni Carbotta, Filippo Maria Di Matteo, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
International Journal of Oncology|March 29, 2017
Expression and prognostic value of the cell polarity PAR complex members in thyroid cancerChiara Tuccilli, Enke Baldini, Yannick Arlot-Bonnemains, et al.
Molecular and Cellular Endocrinology|January 17, 2017
Deregulated expression of VHL mRNA variants in papillary thyroid cancerEnke Baldini, Chiara Tuccilli, Yannick Arlot-Bonnemains, et al.
Cancers|July 29, 2023
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic ReviewClaudio Spinelli, Marco Ghionzoli, Linda Idrissi Sahli, et al.
Endocrine|April 2, 2026
The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitroSilvia Martina Ferrari, Francesca Ragusa, Giusy Elia, et al.
Pageof 27

Showing results (251-260 of 270) with videos related to

Sort By:
Pageof 27
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Cancers|December 9, 2020
Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational StudySalvatore Sorrenti, Giovanni Carbotta, Filippo Maria Di Matteo, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
International Journal of Oncology|March 29, 2017
Expression and prognostic value of the cell polarity PAR complex members in thyroid cancerChiara Tuccilli, Enke Baldini, Yannick Arlot-Bonnemains, et al.
Molecular and Cellular Endocrinology|January 17, 2017
Deregulated expression of VHL mRNA variants in papillary thyroid cancerEnke Baldini, Chiara Tuccilli, Yannick Arlot-Bonnemains, et al.
Cancers|July 29, 2023
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic ReviewClaudio Spinelli, Marco Ghionzoli, Linda Idrissi Sahli, et al.
Endocrine|April 2, 2026
The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitroSilvia Martina Ferrari, Francesca Ragusa, Giusy Elia, et al.
Pageof 27